On March 30, Rendu Biotechnology was listed on SSE Star Market, stock code: 688193. The issue price is 72.65 per share, and a total of 136,100 shares were issued.

From 2018 to 2021, Rendu Biotechnology has achieved operating revenue of CNY 69,343,400, CNYC 99,168,100, CNY 249,934,000 and CNY 292,306,200 respectively, with a compound growth rate of 89.84% from 2018 to 2020, demonstrating good growth momentum and growth potential.

About Rendu Biotechnology (CACLP BOOTH: A1-1712)

Established in 2007, Rendu Biotechnology is a high-tech enterprise focusing on RNA molecular diagnostic technology and products in China, dedicated to developing and promoting RNA molecular diagnostic products based on real-time fluorescence thermostatic amplification technology (SAT technology). It has a complete set of independent intellectual property core technologies from diagnostic reagents to fully automated supporting instruments development and production. At present, the company has successfully established the SAT technology platform, 42 related patents have been granted, and 20 products have obtained NMPA registration certificates and are on sale. Compared with DNA molecular diagnostic technology (PCR), SAT technology has the characteristics of high sensitivity, high specificity, low cross-contamination and easy to achieve fully automated high-throughput detection. SAT-based molecular diagnostic products can be widely used in clinical testing, blood screening, food safety testing, emergency prevention and control of infectious diseases and rapid response.